Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012
|
|
|
- Emil Floyd
- 6 years ago
- Views:
Transcription
1 Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012 These protocols were provided by customers. Under no circumstances shall Zytomed Systems be liable for any damages arising out of the use of these protocols. BM Ultra = BenchMark Ultra BM XT = BenchMark XT BenchMark and NexES as well as iview TM and UltraView TM are registered trademarks of Ventana Medical Systems, Inc. Pre-tre. Description Cat. No. Dil. Enzyme Prefix CC1 CC2 Nexus Incubation AK Ampl. UltraWash Detection Instrument Actin, Smooth Muscle MSK030 1:100 8 min 16 min 37 C UltraView BM Actin, Smooth Muscle MSK030 1: min 32 min 37 C iview DAB BM XT Actin, Smooth Muscle MSK030 1: min 32 min 37 C Ultra View DAB BM XT Actin, Smooth Muscle MSK030 1: min 32 min 37 C iview DAB BM XT Actin, Smooth Muscle MSK030 1: min 24 min 37 C yes Ultra View DAB BM Ultra Annexin A1 MSK : min 32 min 37 C UltraView BM ß-Catenin MSK048 1: min 32 min 37 C UltraView BM Bcl-2 RBK016 1: min 24 min 37 C yes Ultra View DAB BM Ultra Bcl-6 MSK037 1:40 60 min 40 min 37 C iview DAB BM XT Bcl-6 MSK037 1: min 60 min 37 C iview DAB BM XT Calretinin RBK003 1: min 24 min 37 C yes Ultra View DAB BM Ultra Calretinin RBK003 1: min 32 min 37 C iview DAB CD3 BMS002 RTU 60 min 32 min 37 C yes Ultra View Red AP CD3 RBK024 1: min 24 min 37 C yes Ultra View DAB BM Ultra CD5 RBK :50 30 min 32 min 37 C Ultra View DAB BM XT CD5 RBK :50 30 min 32 min 37 C iview DAB BM XT CD8 MSK011 1:50 8 min 16 min 37 C UltraView BM CD10 MSK070 1:25 8 min 16 min 37 C UltraView BM CD15 MSK005 1:50 60 min 32 min 37 C iview DAB BM XT CD15 MSK005 1:50 60 min 32 min 37 C iview DAB BM XT CD15 MSK005 1:100 8 min 32 min 37 C Ultra View BM XT CD15 MSK005 1: min 32 min 37 C iview DAB BM XT CD20 BMS003 RTU 60 min 10 min 37 C yes Ultra View Red AP CD20 MSK008 1: min 24 min 37 C yes Ultra View DAB BM Ultra CD21 RBK036 1:50 8 min 16 min 37 C UltraView BM CD45 LCA MSK054 1:50 8 min 16 min 37 C UltraView BM CD45 LCA MSK054 1:50 30 min 32 min 37 C iview BM CD45 LCA MSK054 1: min 24 min 37 C yes Ultra View DAB BM Ultra
2 CD45 LCA BMS004 RTU 60 min 12 min 37 C yes Ultra View Red AP CD68 MSK055 1: min 30 min 37 C Ultra View BM XT CD68 MSK055 1: min 24 min 37 C yes Ultra View DAB BM Ultra CD79a BMS005 RTU 60 min 32 min 37 C yes Ultra View Red AP CD79a MSK036 1:50 8 min 16 min 37 C UltraView BM CD117 / c-kit RBK021 1: min 28 min 37 C yes Ultra View DAB BM Ultra CD138 MSK063 1:200 8 min 16 min 37 C UltraView BM Cdx2 RBK019 1:50 8 min 32 min 37 C yes Ultra View DAB Cdx2 RBK019 1:50 30 min 32 min 37 C UltraView BM Cdx2 RBK019 1:50 30 min 32 min 37 C iview BM Cdx2 RBK019 1: min 60 min 37 C Ultra View DAB BM XT Cdx2 RBK019 1: min 32 min 37 C Ultra View DAB BM XT Cdx2 RBK019 1: min 24 min 37 C yes Ultra View DAB BM Ultra CEA MSG022 RTU 60 min 6 min 37 C yes Ultra View Red AP CEA MSK022 1: min 24 min 37 C yes Ultra View DAB BM Ultra Chromogranin A MSK062 1:50 36 min 28 min 37 C yes Ultra View DAB BM Ultra Chromogranin A MSK062 1: min 32 min 37 C yes Ultra View DAB BM XT Chromogranin A MSK062 1: min 32 min 37 C iview DAB BM XT CK5/6 MSK034 1:100 Boric acid 32 min 37 C Nexus CK5/6 MSK034 1:50 30 min 32 min 37 C UltraView BM CK7 MSK032 1: min 24 min 37 C yes Ultra View DAB BM Ultra CK7 MSK032 1: min 32 min 37 C iview DAB BM XT CK18 MSK016 1: min 24 min 37 C yes Ultra View DAB BM Ultra CK19 MSK017 1:200 8 min 16 min 37 C UltraView BM CK19 MSK017 1: min 32 min 37 C iview BM CK19 MSK017 1: min 32 min 37 C iview DAB BM XT CK AE1/AE3 MSK019 1:80 36 min 32 min 37 C iview DAB BM XT CK AE1/AE3 MSK019 1: min 32 min 37 C iview DAB BM XT CK AE1/AE3 MSK019 1: min 20 min 37 C Ultra View DAB CK HMW MSK027 1:100 P1 / 8 min 32 min 37 C yes Ultra View DAB BM Ultra Desmin BMS007 RTU 60 min 28 min 37 C yes Ultra View Red AP Desmin MSK053 1: min 24 min 37 C yes Ultra View DAB BM Ultra Desmin MSK053 1: min 32 min 37 C iview DAB BM XT DOG :50 30 min 32 min 37 C iview DAB BM XT DOG : min 32 min 37 C Ultra View DAB BM XT DOG : min 32 min 37 C iview DAB BM XT E-Cadherin MSK033 1:10 30 min 20 min 37 C Ultra View DAB E-Cadherin MSK033 1:80 60 min 28 min 37 C Ultra View DAB BM XT E-Cadherin MSK033 1:80 60 min 32 min 37 C iview DAB BM XT E-Cadherin MSK033 1: min 28 min 37 C yes Ultra View DAB BM Ultra EGFr BMS024 RTU yes 32 min 37 C Ultra View DAB BM XT
3 EGFr MSK014 1:100 P1 / 8 min 30 min 37 C Ultra View BM XT EMA MSK059 1: min 24 min 37 C yes Ultra View DAB BM Ultra EMA MSK059 1:200 8 min 16 min 37 C UltraView BM EMA MSK059 1: min 32 min 37 C iview BM EMA MSK059 1:400?? 20 min 37 C iview DAB BM XT ER (SP1) RBK018 1:50 30 min 57 min 37 C Ultra View DAB ER (SP1) RBK018 1: min 32 min 37 C Ultra View DAB BM XT ER (SP1) RBK018 1: min 28 min 37 C yes Ultra View DAB BM Ultra ERG CM421? 52 min 32 min 37 C iview ERG CM421? 30 min 16 min 37 C Ultra View ESA RTU 30 min 32 min 37 C yes Ultra View DAB BM XT Glypican-3 MSG067 RTU 60 min 30 min 37 C yes Ultra View Red AP Glypican-3 MSK067 1:100 8 min 16 min 37 C UltraView BM Glypican-3 MSK067 1: min 40 min 20 C yes Ultra View DAB BM XT Glypican-3 MSK067 1: min 32 min 37 C Ultra View DAB BM XT Glypican-3 MSK067 1: min 32 min 37 C iview DAB BM XT Glypican-3 MSK067 1: min 32 min 37 C Ultra View DAB BM XT Glypican-3 MSK067 1: min 32 min 37 C iview DAB BM XT Glypican-3 MSK067 1: min 32 min 37 C Ultra View DAB BM XT Helicobacter RBK012 1:600 8 min 32 min 37 C yes Ultra View Red AP Helicobacter RBK012 1: min 32 min 37 C UltraView BM Helicobacter RBK012 1: min 32 min 37 C iview BM Helicobacter RBK012 1:200 8 min 32 min 37 C iview DAB BM XT Helicobacter RBK012 1: min 32 min 37 C iview DAB BM XT Her2 (SP3) * RBK026 1:25 30 min 32 min 42 C yes iview DAB BM Ultra Her2 (SP3) RBK026 1:75 30 min 32 min 37 C Ultra View DAB BM XT Her2 (SP3) RBK026 1: min 32 min 37 C yes Ultra View DAB BM Ultra Her2 (SP3) RBK026 1: min 20 min 37 C yes Ultra View DAB BM Ultra IgG4 MSK084 1: min 30 min 37 C Ultra View DAB BM XT Ki67 BMS009 RTU 60 min 32 min 37 C yes Ultra View Red AP Ki67 MSK018 1: min 40 min 37 C iview DAB BM XT Ki67 MSK018 1: min 32 min 37 C iview DAB BM XT Ki67 MSK018 1: min 32 min 37 C Ultra View DAB BM XT Ki67 MSK018 1: min 32 min 37 C iview DAB BM Ultra Ki67 MSK018 1: min 32 min 37 C yes Ultra View DAB BM Ultra Ki67 MSK018 1: min 32 min 37 C yes Ultra View Red AP Ksp-Cadherin MSK068 1:100 8 min 16 min 37 C UltraView BM LYVE1 RBK014 1:50 60 min 44 min 42 C yes Ultra View DAB MAdL MSK :100 P1 / 8 min 60 min RT UltraView Dab v3 BM Mammaglobin RBK :100 8 min 16 min 37 C UltraView BM Mammaglobin RBK : min 32 min 37 C iview BM
4 Melan-A / MART-1 MSK056 1: min 24 min 37 C yes Ultra View DAB BM Ultra Melanoma / HMB45 BMS010 RTU 60 min 24 min 37 C yes Ultra View Red AP Melanoma / HMB45 MSK007 1: min 24 min 37 C yes Ultra View DAB BM Ultra MLH1 MSK045 1:25 x* 90 min 180 min 37 C yes NO!! Ultra View DAB v3 BM XT MLH1 MSK045 1:25 x 90 min 60 min 37 C yes NO!! Ultra View DAB BM MSH2 MSG031 RTU 30 min 32 min 37 C yes yes Ultraview Red BM XT Myosin, SM MSK :100 8 min 16 min 37 C UltraView BM Myosin, SM MSK : min 32 min 37 C iview BM Oct-2 MSK :50 30 min 32 min 37 C iview BM p53 MSK020 1: min 28 min 37 C yes Ultra View DAB BM Ultra p53 MSK020 1: min 32 min 37 C iview DAB BM XT PD-1 MSK :50 30 min 32 min 37 C UltraView BM Pax-8 RBK :50 60 min 60 min 37 C Ultra View DAB BM XT PIN Cocktail CO001K 1:50 52 min 32 min 37 C yes Ultra View DAB BM Ultra PIN Cocktail CO001K 1:50 60 min 32 min 37 C iview DAB BM XT PIN Cocktail CO001K 1:75 90 min 32 min 37 C iview DAB BM XT PIN Cocktail CO001K 1:80 60 min 32 min 37 C iview DAB BM XT PMS2 MSK :25 60 min 32 min 37 C yes iview DAB BM XT PMS2 MSK :50 8 min 44 min RT PMS2 RBG048 RTU 30 min 32 min 37 C yes Ultra View DAB BM XT PLAP MSK047 1: min 32 min 37 C yes Ultra View Red AP PLAP MSK047 1:50 30 min 32 min 37 C UltraView BM Podoplanin / D2-40 MSK057 1:50 30 min 32 min 37 C UltraView BM Podoplanin / D2-40 MSK057 1:50 30 min 32 min 37 C iview BM Podoplanin / D2-40 MSK057 1:50 Boric acid 32 min 37 C Nexus PR (SP42) RBK020 1: min 57 min 37 C Ultra View DAB PR (SP42) RBK020 1: min 28 min 37 C yes Ultra View DAB BM Ultra PR (SP42) RBK020 1: min 32 min 37 C Ultra View DAB BM XT PR (SP42) RBK020 1: min 32 min 37 C yes Ultra View DAB BM Ultra PR (SP42) RBK020 1: min 32 min 37 C Ultra View DAB BM XT PR (SP42) RBK020 1: min 32 min 37 C iview DAB BM XT PSA MSK051 1:200 8 min 16 min 37 C UltraView BM PSA MSK051 1: min 32 min 37 C iview BM PSA MSK051 1: min 32 min 37 C yes Ultra View DAB BM Ultra S100 BMS013 RTU 60 min 8 min 37 C yes Ultra View Red AP S100 MSK050 1: min 24 min 37 C yes Ultra View DAB BM Ultra SSTR2A RBK : min 24 min 37 C no Ultra View AP Red BM Ultra Synaptophysin RBK011 1:400 8 min x min RT? Ultra View BM XT Synaptophysin RBK011 1: min 28 min 37 C yes Ultra View DAB BM Ultra Synaptophysin : min 32 min 37 C yes Ultra View Red AP Tenascin :100 8 min 32 min 37 C Ultra View DAB BM XT
5 Thyroglobulin MSK039 1:100 8 min 16 min 37 C UltraView BM Thyroglobulin MSK039 1: min 32 min 37 C iview BM Trypsin RBK055 1:100 P1 / 8 min 32 min 37 C Ultra View DAB BM Ultra TTF-1 MSK004 1: min 32 min 37 C yes Ultra View Red AP TTF-1 MSK004 1: min 28 min 37 C yes Ultra View DAB BM TTF-1 MSK004 1: min 32 min 37 C yes Ultra View DAB BM Ultra TTF-1 MSK004 1: min 60 min 37 C Ultra View DAB BM XT TTF-1 MSK004 1: min 32 min 37 C Ultra View DAB BM XT TTF-1 MSK004 1: min 32 min 37 C iview DAB BM XT Uroplakin III MSK052 1:10 Boric acid 32 min 37 C Nexus uroplakin III MSK052 1:50 P1 / 10 min 30 min 37 C Ultra View DAB BM Uroplakin III MSK052? 60 min 40 min 42 C yes UltraView Dab v3 BM XT Vimentin (V9) MSK023 1: min 32 min 37 C iview DAB BM XT Vimentin (V9) BMS012 RTU 60 min 6 min 37 C yes Ultra View Red AP Her2 (SP3) * special protocol for HER2 on stomach P1: equivalent to Pronase P2: equivalent to Trypsin P3: equivalent to Ficin CC1: EDTA/Boric acid buffer ph 8.4 x* Fixativ I = Prefix (with empty Prepkit) 10% buffered Formaldehyd (stronger than usual ) 24 minutes CC2: Citrate buffer ph 6.0 Tip from customer: Prefix with mmr-antibodies works very well
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK UCL-Advanced Diagnostics 1st Floor, Rockefeller Building 21 University Street London WC1E 6JJ Contact: David Allen Tel: +44 (0)20 7679 6912
In Situ Hybridization Immunohistochemistry
2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco
The impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
ADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents
2017 ADVANCED STAINING PRODUCT CATALOG In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents A History of Delivering Superior Products Genemed a wholly-owned
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005
IHC Reagents & Kits. CE/IVD Certified
IHC Reagents & Kits CE/IVD Certified BioSiteHisto Nordic BioSite wants to make diagnostic work easier. For this purpose, we have selected a number of markers, which are frequently needed for diagnostics
Differential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
recommended for detecting myoepithelial cells.
Myosin SMMHC stained on normal breast tissue (MSK081) p63 stained on breast carcinoma (MSK087) The expanding role of immunohistochemistry in from atypical ductal hyperplasia or low-grade breast pathology
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Immunohistochemistry. Potential and challenges To be or not to be
Immunohistochemistry Potential and challenges To be or not to be Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Vårmöte 19.05.2016 Karlstad Overview IHC project coordinator at
IHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
Breast cancer: Antibody selection, protocol optimzation controls and EQA
Breast cancer: Antibody selection, protocol optimzation controls and EQA Workshop in Diagnostic Immunohistochemistry Oud St. Jan/ Old St. John Brugge (Bruges), Belgium June 13th 15nd 2018 Rasmus Røge,
Histopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
International Catalogue 2016/2017
Detection Cell Control Arrays Accessory Reagents International Catalogue 2016/2017 Immunohistochemistry Selected Reagents for Diagnostics and Research Content Antibodies Positive control list for primary
The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
Estrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
Assessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
Assessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
The clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
Assessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana
10 years of NordiQC Why are 30% of labs still getting it wrong?
Mogens Vyberg & Søren Nielsen NordiQC Institute of Pathology Aalborg University Hospital Aalborg, Denmark May 29th 2015 10 years of NordiQC Why are 30% of labs still getting it wrong? Nothing to declare
Assessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
Nordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
Assessment Run NKX3.1 (NKX3.1)
Assessment Run 49 2017 NKX3.1 (NKX3.1) Material The slide to be stained for NKX3.1 comprised: 1. Testis 2. Appendix 3-4. Prostate adenocarcinoma 5. Prostate hyperplasia All tissues were fixed in 10% neutral
antibodies by application
antibodies by application Higher Affinity Higher Sensitivity Higher Specificity A selection of Over 460 Rabbit and Mouse Monoclonal For Use in Clinical and Research Applications Bio SB s RBT & MMab s BSB
Quality Assurance in Immunohistochemistry: Experiences from NordiQC
Nordic immunohistochemical Quality Control 2 Quality Assurance in Immunohistochemistry: Experiences from NordiQC Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg University Hospital Aalborg,
Thyroid transcription factor-1 (TTF1) Assessment run
Thyroid transcription factor- (TTF) Assessment run 39 203 The slide to be stained for TTF comprised:. Thyroid gland, 2. Liver, 3. Normal lung, 4. Lung adenocarcinoma 5. Colon adenocarcinoma, 6 & 7. Lung
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 05/09/2018 Cellular Pathology Level 2 Esher Wing Galsworthy Road Kingston upon Thames KT2 7QB Contact: Dr Sussan Gharaie Tel: +44 (0)208 934
DOUBLE STAINS. Toll-Free: Direct:
DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Calderdale and Huddersfield NHS Foundation Trust Calderdale Royal Hospital Salterhebble Halifax HX3 0PW United Kingdom Contact: Dr Richard
Reporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
Zytomed Systems GmbH
Zytomed Systems GmbH Anhaltiner Straße 16 14163 Berlin hone +49 30 80 49 84 990 Fax +49 30 80 49 84 999 international@zytomed-systems.de www.zytomed-systems.com 2 Content ositive control list for primary
Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System
Thermo Scientific for Immunohistochemistry The New Generation Micro-Polymer Detection System highest sensitivity sharp crisp clear shorter incubation times UltraVision Quanto the new Micro-Polymer System
Assessment Run
Assessment Run 50 2017 S100 Material The slide to be stained for S100 comprised: 1. Appendix, 2. Tonsil, 3. Schwannoma, 4-5. Malignant melanoma, 6. Colon adenocarcinoma. All tissues were fixed in 10% neutral
Sal-like protein 4 (SALL4)
Assessment Run 43 205 Sal-like protein 4 (SALL4) The slide to be stained for SALL4 comprised:. Appendix, 2. Testis, 3. Renal clear cell carcinoma, 4. Seminoma, 5. Intratubular germ cell neoplasia (IGCN),
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 002 Issue date: 05 March 2018 Berkshire and Surrey Pathology Services Department of Histopathology Wexham Park Hospital Slough Berkshire
Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment
Reprinted by permission of UK NEQAS Immunocytochemistry and David S. Gray Kind thanks to David S. Gray for allowing ThermoFisher Scientific, Lab Vision Products, to distribute this article. Immunocytochemistry
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK operating as North East Essex and Suffolk Pathology Service (NEESPS) Cellular Pathology Contact: Lynn Partridge Ipswich Hospital Tel: +44
Ready-to-use, CE-IVD antibodies for pathology
A-1-Antichymotrypsin A-1-Antitrypsin Abcc3 Aberrant Endothelial 4A11 Cell ACTH BSB-25; AH26 Actin 1A4 Actin, Muscle Specific HHF35 Actin, Smooth Muscle BSB-15 (ASM/H12) Adenovirus 20/11 and 2/6; A62020069A
Immunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
2016 Antibodies by Application
2016 by Application Higher Affinity Higher Sensitivity Higher Specificity New Rabbit Monoclonal ALK, EP301 Amyloid A, EP335 B7H3/CD276, RBT B7H3 bcl6, EP278 BRAF V600E, RM8 C4d, EP273 CD5, RED1 CD8, EP334
Carcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Christie Hospital Manchester M20 4BX Contact: Neil Wrathall Tel: +44 (0) 161 918 7264 Fax: +44 (0) 161 446 8549 E-Mail: neil.wrathall@christie.nhs.uk
Estrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1
Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases 183 100 histology IDBC 128 70 ILBC 49 27 others 6 3 pt status pt1 98 54 pt2 56 31 pt3 14 8 pt4 14 8 ptx 1 1 pn status
C.L. Davis Foundation Descriptive Veterinary Pathology Course
C.L. Davis Foundation 2015 Descriptive Veterinary Pathology Course IHC Resources IHC Identification Targets Antibodies Antibodies 1 Antibodies Specimens Antigen Retrieval Unmasks antigen epitopes Methods
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service ccredited to Department of Cellular & Molecular Pathology ntrim LBS ntrim rea Hospital 45 Bush Road ntrim BT41 2RL Contact: Jackie Jamison Tel:
SMH (Myosin, smooth muscle heavy chain)
Material The slide to be stained for SMH comprised: Assessment Run 50 2017 SMH (Myosin, smooth muscle heavy chain) 1.Tonsil, 2. Esophagus, 3. Breast hyperplasia, 4. Breast ductal carcinoma in situ (DCIS),
Instant Quality FISH. The name says it all.
COMPANION DIAGNOSTICS Instant Quality FISH Instant Quality FISH. The name says it all. IQ: Instant Quality every time. Breast carcinoma stained with : Triple filter showing Blue DAPI colors nuclei, FITC
NEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
TEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
Immunohistochemical principles The technical test approach. Pre-analytical parametres
Immunohistochemical principles The technical test approach Pre-analytical parametres Søren Nielsen Global Pathology Manager Agilent Technologies (Former Scheme Manager, NordiQC) 2 IHC project coordinator
Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Role of immunohistochemistry in the differential diagnosis of malignant small round cell tumor: a study of 38 cases
International Journal of Research in Medical Sciences Patel A et al. Int J Res Med Sci. 2015 Dec;3(12):3833-3839 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20151452
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Blizard Institute Core Pathology Pathology and Pharmacy Building Second Floor 80 Newark Street London E1 2ES Contact: Pauline Levey Tel: +44
Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami
Ascitic Fluid and Use of Immunocytochemistry Mercè Jordà, University of Miami Is It Malignant? Yes? No Ascitic Fluid Cytomorphologic Useful Findings Tight clusters with smooth borders Cellular and nuclear
I have nothing to disclose
A 47 year old female with multiple lung nodules Disclosure of Relevant Financial Relationships Tamar Giorgadze, MD, PhD Professor of Pathology Medical College of Wisconsin Milwaukee, Wisconsin USCAP requires
Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology
DOI:10.1093/jnci/djt099 Article JNCI Journal of the National Cancer Institute Advance Access published May 2, 2013 The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions,
Solutions for IHC. Immunohistochemistry Products 2018 Catalog
Solutions for IHC Immunohistochemistry Products 2018 Catalog Immunohistochemistry Products In an industry where seemingly small decisions can have huge implications and the quality of your diagnosis is
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK The Princess Alexandra Hospital NHS Trust The Michael Letcher Department of Cellular Pathology The Princess Alexandra Hospital NHS Trust Hamstel
Estrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
IIImmunohistochemistry (IHC) Outreach Services
IIImmunohistochemistry (IHC) Outreach Services Note type of fixative used if not neutral buffered formalin. Note type of tissue/specimen Unless specified otherwise, positive and negative controls react
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK North Tyneside General Hospital Rake Lane North Shields Tyne & Wear NE29 8NH Contact: Ian Taylor Tel:
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Contact: Dr Nicola Chaston East Kent Hospitals University Tel: +44 (0)1233 616183 NHS Foundation Trust Fax: +44 (0) 01233
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES Mahul B. Amin Professor & Chairman Department of Pathology & Laboratory Medicine Cedars-Sinai
Optimization of antibodies, selection, protocols and controls Breast tumours
Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin
Single and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
Special slide seminar
Special slide seminar Tomáš Rozkoš The Fingerland Department of Pathology Charles University Medical Faculty and Faculty Hospital in Hradec Králové Czech Republic Case history, 33 years old resistance
HSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
Lung Anaplastic Lymphoma Kinase (lu-alk)
Assessment Run 5 207 Lung Anaplastic Lymphoma Kinase (lu-alk) Material The slide to be stained for lu-alk comprised:. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma with
Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
External Quality Assessment of Breast Marker Analysis. NordiQC data
External Quality Assessment of Breast Marker Analysis NordiQC data Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Aalborg 12.06 2015 Markers assessed in NordiQC Predictive markers
Consultation interface between Pathologists and Forensic Science Experts for histopathology examination
Consultation interface between Pathologists and Forensic Science Experts for histopathology examination V. Cirielli a,b, M. Brunelli c, F. Bortolotti a, Z. De Battisti a, G. Del Balzo a, A. De Salvia a,
Immunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
Epithelial cell-cell adhesion molecule (Ep-CAM)
Assessment Run 3 011 Epithelial cell-cell adhesion molecule (Ep-CAM) Material The slide to be stained for Ep-CAM comprised: 1. Appendix,. Kidney, 3. Adrenal gland, 4. Lung carcinoid, 5 & 6. Renal clear
Assessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Dorset County Hospital Williams Avenue Dorchester DT1 2JY Contact: Sharon Wood Tel: +44 (0)1305 254326 E-Mail:
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer
Media Release Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer The VENTANA MMR IHC Panel 1 helps differentiate between sporadic colorectal cancer
Zyto-Facts Editorial. News for Pathology and Immunohistochemistry. +++ Newsflash +++ Newsflash +++
Zyto-Facts 1-2016 News for Pathology and Immunohistochemistry Editorial The primary site of a tumor is not known in about 3 % to 5 % of all cancer diagnoses. Patients, whose primary site could be identified,
Section 14 Other Cancers. Cancer of Unknown 113 Primary Site INTRODUCTION PATHOLOGIC EVALUATION
Section 14 Other Cancers Cancer of Unknown 113 Primary Site F. Anthony Greco and John D. Hainsworth INTRODUCTION Cancer of unknown primary (CUP) site is a clinical syndrome that includes many types of
HistoCyte Laboratories Ltd
HistoCyte Laboratories Ltd Progesterone Receptor: The neglected breast receptor! Dr Ian Milton & Colin Tristram November 2018 UKNEQAS Autumn meeting Introduction Progesterone is an important prognostic
Speaking to you. This statement by Dr. Rodney T. Miller, Director of
Zyto_Facts 1-2013 News for pathology and immunohistochemistry +++Newsflash +++ Newsflash++ Speaking to you IHC algorithm poster now available in English. You can download the poster directly from our homepage
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Laboratory locations: Department of Histopathology Royal United Hospitals NHS Foundation Trust Combe Park Bath BA1 3NG Contact: Lesley Shipway
Cleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special s Group I for Microorganisms Special s Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram Gridley PAS/light green counterstain Warthin-Starry
Cytokeratin 19 (CK19)
Assessment Run 34 202 Cytokeratin 9 (CK9) Material The slide to be stained for CK9 comprised:. Thyroid gland, 2. Appendix, 3. Esophagus, 4. Papillary thyroid carcinoma, 5 & 6. Pancreatic neuroendocrine
Cleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special Stains Group I for Microorganisms Special Stains Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram PAS/light green counterstain Warthin-Starry
Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay
Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay F. Anthony Greco, Wayne J. Lennington, David R. Spigel & John D. Hainsworth Molecular
CytoLyt fixa+on and decalcifica+on pretreatments alter an+genicity in normal +ssues compared to standard formalin fixa+on
CytoLyt fixa+on and decalcifica+on pretreatments alter an+genicity in normal +ssues compared to standard formalin fixa+on Penny Barnes, MD, FRCP(C) Capital Health District Health Authority and Dalhousie
Establishing a definitive pathologic diagnosis in surgical
SPECIAL ARTICLE Best Practices in the Application of Immunohistochemistry in Urologic Pathology Report From the International Society of Urological Pathology Consensus Conference Mahul B. Amin, MD,* Jonathan